反应详情

Using the procedure outlined in Example 1(g) the title compound was prepared from (4S)-4-(4-amino-benzyl)-1,3-oxazolidin-2-one (46 mg, 0.24 mmol) and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1(e) above, 100 mg, 0.24 mmol). The title compound was obtained as a white solid (56 mg, 44%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.00 (br, 1H), 8.42 (s, 1H), 7.50 (br, 1H), 7.33 (d, J=7.9 Hz, 1H), 7.28 (br, 2H), 7.18 (s, 1H), 7.08 (d, J=7.8 Hz, 1H), 6.81 (br, 2H), 5.88 (s, 1H), 4.41 (t, J=8.2 Hz, 1H), 4.31 (q, J=7.0 Hz, 2H), 4.05 (m, 1H), 3.98 (m, 1H), 2.99 (t, J=7.4 Hz, 2H), 2.92 (t, J=7.4 Hz, 2H), 2.79-2.66 (m, 2H), 2.15 (m, 2H), 1.31 (t, J=7.1 Hz, 3H).